• [Hankyung BIO Insight] EOPatch's CE audit is scheduled for this month…plans to launch in Europe in 2H21

  • EOFlow's EOPatch CE surveillance audit plan was introduced on Hankyung BIO Insight on 04/07/2021 (in Korean only):

    In summary, Reporter Yena Kim explained that EOPatch's CE surveillance audit is scheduled from April 20 and following the CE MDD marking by the end of May, Europe launch is expected in 2H21. 
    EOFlow's wearable, disposable insulin patch will be distributed in the European market by Menarini, under its brand. 
    Reporter emphasized that EOPatch will be able to secure market share in Europe with Menarini. 

    Moreover, the reporter explained that EOFlow plans to develop two wearable artificial pancreas projects: EOPatchX and EOPancreas. 
    EOPatchX is a two-part wearable artificial pancreas with the 3rd party CGM sensor and AP algorithm. EOPancreas is a single-patch which combines CGM/AP algorithm/EOPatch. 

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here